Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, open-label, 3-period, 3-treatment multiple-dose
crossover study designed to assess the interaction between VYTORIN® (Ezetimibe and
Simvastatin) and NIASPAN® (Niacin Extended-Release Tablets) in healthy subjects. Treatment
spans 7 days
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Niacin Niacinamide Nicotinic Acids Simvastatin